Author + information
- Lukasz Koltowski,
- Janusz Kochman,
- Mariusz Tomaniak,
- Arkadiusz Pietrasik,
- Klaudia Proniewska,
- Jacek Jakala,
- Adam Rdzanek,
- Krzysztof Filipiak and
- Grzegorz Opolski
Background: The everolimus-eluting bioresorbable vascular scaffold (BVS) is a new technology that was designed to alleviate some of the drawbacks of metallic drug eluting stents (DES).
Methods: The aim of the study was to evaluate the vascular healing pattern and device performance using the OCT over the second year after BVS implantation. BVS was implanted during the primary percutaneous coronary intervention in consecutive STEMI patients. A 12- and 24-months OCT follow-up has been scheduled as part of the study protocol. In 14 patients the corresponding 12- and 24-month OCT follow-up was available and evaluated. The OCT analysis was performed at 1 mm longitudinal intervals. For the 5-mm proximal and distal edges as well as at the 2-mm margins of the scaffold the edge vascular restenosis was assessed in a frame-by-frame fashion. The following OCT parameters were evaluated: lumen and scaffold area, strut malapposition and neointimal thickness.
Results: Between 12 and 24 months after BVS implantation a significant increase in the mean neointimal thickness of 89μm was recorded. Despite that, the minimum and mean lumen was not diminished, which could likely be explained by the concomitant enlargement of the mean and minimal scaffold area. No late malapposition or device failures were reported during the observation period.
Conclusions: The vascular response to the BVS implanted in STEMI patients evaluated with OCT between 12- and 24-months confirmed safety and efficacy of the device.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes
Abstract Category: 2. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number: 1166-334
- 2017 American College of Cardiology Foundation